Roche's drug is the first cancer immunotherapy to be approved by the FDA for adjuvant treatment of NSCLC ... and patients a new way to treat early lung cancer that has the potential to ...

Do patients with early-stage non–small cell lung cancer (NSCLC ... with resectable NSCLC benefit from immunotherapy in both the neoadjuvant and adjuvant settings, the advisory panel did not ...

Active specific immunotherapy; BCG: Bacille Calmette–Guérin; KLH: Keyhole limpet hemocyanin; MPL: Monophosphoryl lipid A; NSCLC: Non-small-cell lung cancer. Various adjuvant products are ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

The efficacy of immunotherapy against triple-negative breast cancer (TNBC) heavily relies on intratumoral infiltration of ...

Cancer is now the second leading cause of death worldwide, and rates are climbing-especially in younger adults. Breast, ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors. It has made an incredible impact on treating cancers in many different organ ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...